Edward B. Singleton Department of Radiology, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.
Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Natl Cancer Inst. 2023 Nov 8;115(11):1262-1270. doi: 10.1093/jnci/djad151.
The Immuno-Oncology Translational Network (IOTN) was established in 2018 as part of the Cancer Moonshot. In 2022, President Joe Biden set new goals to reduce the cancer death rate by half within 25 years and improve the lives of people with cancer and cancer survivors. The IOTN is focused on accelerating translation of cancer immunology research, from bench to bedside, and improving immunotherapy outcomes across a wide array of cancers in the adult population. The unique structure and team science approach of the IOTN is designed to accelerate discovery and evaluation of novel immune-based therapeutic and prevention strategies. In this article, we describe IOTN progress to date, including new initiatives and the development of a robust set of resources to advance cancer immunology research. We summarize new insights by IOTN researchers, some of which are ripe for translation for several types of cancers. Looking to the future, we identify barriers to the translation of immuno-oncology concepts into clinical trials and key areas for action and improvements that are suitable for high-yield investments. Based on these experiences, we recommend novel National Institutes of Health funding mechanisms and development of new resources to address these barriers.
免疫肿瘤转化网络（IOTN）于 2018 年作为癌症登月计划的一部分成立。2022 年，乔·拜登总统设定了新目标，即在 25 年内将癌症死亡率降低一半，并改善癌症患者和癌症幸存者的生活。IOTN 专注于加速癌症免疫学研究从实验室到临床的转化，并改善成年人群体中广泛癌症的免疫疗法效果。IOTN 的独特结构和团队科学方法旨在加速新型免疫治疗和预防策略的发现和评估。在本文中，我们描述了 IOTN 迄今为止的进展，包括新的举措和开发了一套强大的资源，以推进癌症免疫学研究。我们总结了 IOTN 研究人员的新见解，其中一些已经为几种类型的癌症的转化做好了准备。展望未来，我们确定了将免疫肿瘤学概念转化为临床试验的障碍，以及适合高收益投资的行动和改进的关键领域。基于这些经验，我们建议采用新的美国国立卫生研究院资助机制和开发新资源来解决这些障碍。
